Take part in a paid clinical trial

We’re currently looking for adults aged 18 to 65 who are experiencing androgenetic alopecia (AGA), also known as pattern hair loss, to take part in The Headline Trial.

Hair loss is common and can affect both men and women. This clinical study is investigating new approaches that may help shape future treatment options.

You don’t need a formal diagnosis to get started. If you think you may have AGA, you can begin with a quick pre-screen. This helps us assess whether you may meet the initial study requirements. Completing the pre-screen doesn’t guarantee enrolment, but it’s an important first step in seeing whether the study may be suitable for you.

By getting involved, you’ll be contributing to research that aims to improve future options for people affected by hair loss.

Overgrowth conditions are rare disorders where certain parts of the body grow more than they should. This happens because of a change in a gene called PIK3CA, which normally helps control how cells grow. In these conditions, the gene sends too many growth signals, causing extra tissue or abnormal blood vessels to form in specific areas, such as an arm, leg, or part of the body. The change isn’t inherited and only affects some cells, which is why the overgrowth is uneven rather than affecting the whole body. Over time, this extra growth can lead to pain, swelling, movement difficulties, or circulation issues, and may gradually worsen if left untreated. We are looking at a potential new oral treatment for these conditions, due to the limitations in current treatment.

We’re launching a new clinical study exploring an investigational treatment designed for people living with hypoparathyroidism. This rare condition can disrupt the body’s calcium balance, often leading to muscle cramps, tingling, fatigue, and other daily challenges.

Our study focuses on a potential new therapy that aims to restore healthier parathyroid hormone function and improve overall quality of life. By participating, volunteers may help advance research that could lead to new treatment options for the broader hypoparathyroidism community.

This new treatment is being developed because current options for hypoparathyroidism have some major limitations. Right now, most people have to take large amounts of calcium and active vitamin D every day to keep their blood calcium levels stable. While these supplements can help prevent low calcium, they don’t replace the parathyroid hormone (PTH) that the body is missing. As a result, this approach can be hard to manage and may cause other issues over time.

The study drug is being developed to help people with inflammatory bowel disease (IBD). IBD causes ongoing inflammation in the digestive system and includes conditions like Crohn’s disease, ulcerative colitis, and indeterminate colitis. The study explains that there is still a real need for better treatments because current medicines don’t cure IBD, and many people either don’t respond well or stop responding over time.